A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01)
نویسندگان
چکیده
A multi-center study of high dose Aldesleukin (Proleukin®(HD IL-2) + Vemurafenib Zelboraf®) therapy in patients with BRAF mutation positive metastatic melanoma (proclivity 01) Joseph Clark, Lawrence Flaherty, Marc Ernstoff, Henry Koon, Mohammed Milhem, Gerald Militello, Sanjiv Agarwala, Brendan Curti, Lee Cranmer, Christopher D Lao, Theodore F Logan, Jose Lutzky, Venkatesh Rudrapatna, Gregory Daniels, Bret Taback, Sandra Aung, James Lowder, David Lawson
منابع مشابه
Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02)
Prometheus Laboratories, San Deigo, CA, USA Full list of author information is available at the end of the article Figure 1 Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy®) in patients with metastatic melanoma (proclivity 02). Patel et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P78 http://www.i...
متن کاملTreatment for advanced melanoma: new drugs, new opportunities, new challenges.
The standard of care for the treatment of patients with metastatic melanoma has changed fundamentally based on two new treatment strategies that are, conceptually and biologically, largely independent: the blockade of immune regulatory molecules with monoclonal antibodies (termed “immune checkpoint blockade”) and the inhibition of BRAF V600 mutation–driven mitogen-activated protein kinase (MAPK...
متن کاملBRAFV600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study
BACKGROUND Mutations in the BRAF gene have been implicated in several human cancers. The objective of this screening study was to identify patients with solid tumors (other than metastatic melanoma or papillary thyroid cancer) or multiple myeloma harboring activating BRAFV600 mutations for enrollment in a vemurafenib clinical study. METHODS Formalin-fixed, paraffin-embedded tumor samples were...
متن کاملCurrent status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma.
Interleukin-2 (IL-2, Proleukin) is one of the most effective agents in the treatment of metastatic renal cell carcinoma and metastatic melanoma. High-dose IL-2 therapy produces overall response rates of 15% to 20%; however, it is associated with significant toxicities that affect essentially every organ system. Although IL-2-related toxicities are usually reversible with therapy discontinuation...
متن کاملThe outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial
AIM OF THE STUDY The BRAF inhibitor vemurafenib has improved progression-free survival and overall survival in patients with BRAFV600-mutation-positive metastatic melanoma. Here we present the results of an open-label safety study with vemurafenib in patients with metastatic melanoma enrolled in Polish oncological centres. MATERIAL AND METHODS Patients with untreated or previously treated Sta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 2 شماره
صفحات -
تاریخ انتشار 2014